EGFR and neoplasm: We believe that safely increasing IL-1 signaling in combination with cetuximab as a novel immunotherapeutic strategy would be promising in that we would be targeting both the tumor (via EGFR inhibition) resulting in high response rates, and the host innate and adaptive immune system (via increased T-cell responses) resulting in more durable tumor responses.